Vaccine Research with Marc LaForce (NPF Vaccine Webinar Series)


Published on

We discuss the costs associated with research and the difficulty of safe manufacturing. Why are vaccine facilities so difficult to establish? Why are some diseases ignored? What new vaccines are in the pipeline, and how does the threat of bio-terrorism affect the nation’s vaccine agenda?

Special guest: Dr. Marc LaForce, Global Program Leader, Meningitis Vaccine Project, PATH

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Vaccine Research with Marc LaForce (NPF Vaccine Webinar Series)

  1. 1. National Press Foundation Vaccine Webinar SeriesVACCINE RESEARCH Dr. Marc LaForce November 29, 2011
  2. 2. Vaccine ResearchA new meningitis vaccine for Africa Vaccine Webinar Series National Press Foundation November 29, 2011 Marc LaForce, PATH
  3. 3. The road to a new vaccine 3 3
  4. 4. Vaccine manufacturers Five Pharma firms (US/Eur) • Profitable companies • Charge high prices for new vaccines • Concentrate on low-volume rich world markets Emerging suppliers • Traditionally sell older, less complex vaccines • High-volume and low-margin markets • Interest in developing more complex (higher margin) vaccines 4 4
  5. 5. Problems for vaccines aimed at developing country problems Development of new vaccines controlled by Pharma and aimed at products with market potential Very slow introduction of new products to developing countries  Hepatitis B vaccine  HiB conjugate vaccine 5 5
  6. 6. Meningitis in Sub-Saharan Africa• Over 90 percent of global meningococcal disease occurs in the African meningitis belt• Attacks children, young adults and infants• One third of meningitis cases die (10%) or are disabled (23%)• One strain (Group A Nm) accounts for estimated 80% of all meningococcal cases.• Epidemics occur every year• Poorest countries in the world• New vaccine cost is critical to sustainability 6 6
  7. 7. Small clinic for meningitis patients •The “intensive care unit” of Africa •Individuals are treated where they fall •Very few hospitals in this region; makeshift clinics are established when needs arise 7 7
  8. 8. Serum Institute of India Ltd. (SIIL) Largest “emerging supplier” World’s largest producer of measles and DTP Two-thirds of the world’s immunized children are vaccinated by a vaccine manufactured by SIIL Partnered with the Meningitis Vaccine Project to develop an affordable (< $US 0.50 per dose) vaccine designed specifically for Africa to protect against meningococcal meningitis 8 8
  9. 9. 2010 introduction of MenAfriVac™  20 million people in Burkina Faso (100%), Mali (50%), and Niger (50%) vaccinated  In 2011 in Burkina Faso:  Lowest number of reported cases of meningitis  Not a single case of meningitis A in individuals vaccinated with MenAfriVac™  Group immunity established with use of the vaccine 9 9
  10. 10. 10 10
  11. 11. The Meningitis Vaccine Project 11 11
  12. 12. National Press Foundation Vaccine Webinar SeriesVACCINE RESEARCH Q&A Dr. Marc LaForce November 29, 2011